ArticleThe American journal of gastroenterology2018
Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Article in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review.Digestive diseases and sciences · 2022Pooled it
- Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.Alimentary pharmacology & therapeutics · 2023Trial
- Discordance between observer and patient-reported shared decision-making in inflammatory bowel disease: A multicenter cross-sectional study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review.Advances in therapy · 2026Review
- Exploring Information Needs and Perspectives on a Patient Decision Aid for Biologic Therapy: A Qualitative Interview Study Among Individuals with Rheumatoid Arthritis.Patient preference and adherence · 2026Article
- Effectiveness of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis and 5-aminosalicylate intolerance.Medicine · 2025Observational
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.Advances in therapy · 2025Article
- A Quality Assessment and Evaluation of Credible Online Dietary Resources for Patients with an Ileoanal Pouch.Journal of clinical medicine · 2025Article
- Patient preferences for advanced therapies in ulcerative colitis using conjoint analysis.Intestinal research · 2025Article
- Embedding a Choice Experiment in an Online Decision Aid or Tool: Scoping Review.Journal of medical Internet research · 2025Article
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.Inflammatory bowel diseases · 2024Article
- Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.Crohn's & colitis 360 · 2024Article
- Determining patient preferences for the medical management of osteoporosis using conjoint analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Patients' perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media.BMC gastroenterology · 2023Article
- What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study.Journal of Crohn's & colitis · 2023Review
- Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study].Journal of Crohn's & colitis · 2023Article
- Patient-Preference Diagnostics: Adapting Stated-Preference Methods to Inform Effective Shared Decision Making.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- An opponent model for agent-based shared decision-making via a genetic algorithm.Frontiers in psychology · 2023Article
- Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.Health technology assessment (Winchester, England) · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectivesRecent drug approvals have increased the availability of biologic therapies for inflammatory bowel disease (IBD), making it difficult for patients with ulcerative colitis (UC) and Crohn's disease (CD) to navigate treatment options. Here we developed a conjoint analysis to examine patient decision-making surrounding biologic medicines for IBD. We used the results to create an online patient decision aid that generates a unique "preferences report" for each patient to assist with shared decision-making with their provider.
methodsWe administered an adaptive choice-based conjoint survey to IBD patients that quantifies the relative importance of biologic attributes (e.g., efficacy, side effect profile, mode of administration, and mechanism of action) in decision making. The conjoint software determined individual patient preferences by calculating part-worth utilities for each attribute. We conducted regression analyses to determine if demographic and disease characteristics (e.g., type of IBD and severity) predicted how patients made decisions.
results640 patients completed the survey (UC=304; CD=336). In regression analyses, demographics and IBD characteristics did not predict individual patient preferences; the main exception was IBD type. When compared to UC, CD patients were more likely to report side effect profile as most important (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.16-2.30). Conversely, those with UC were more likely to value therapeutic efficacy (OR 1.41, 95% CI 1.01-2.00).
conclusionsBiologic decision-making is highly personalized; demographic and disease characteristics poorly predict individual preferences, indicating that IBD patients are unique and difficult to statistically categorize. The online decision tool resulting from this study (www.ibdandme.org) may be used by patients to support shared decision-making and optimize personalized biologic selection with their provider.
Indexed as
Identifiers
29206816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.